Sesen Bio   Report issue

For profit Phase 1 Phase 3
Founded: Cambridge MA United States (2010)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2012
NCT01748578
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Eleven Biotherapeutics